Monitor the January 2027 pilot for clinical utility results and any subsequent purchase orders from Sirica Therapeutics or the VA. Without disclosed revenue or contractual commitments, this remains a speculative healthcare expansion with no near-term financial impact.
Price Chart
Executive Summary
Virtuix announced a partnership with The LP Foundation to deploy its Omni One platform in a multi-site pilot program starting January 2027, evaluating AI-driven, movement-based therapy for children with autism. The pilot builds on existing work with Rutgers University and Sirica Therapeutics, and follows recent Omni One sales to the VA for rehabilitation applications. This is a non-revenue, early-stage pilot with no financial terms disclosed, representing a speculative expansion into healthcare.
Key Facts
- Multi-site pilot program begins January 2027, involving The LP Foundation, Rutgers University WINLAB, and Sirica Therapeutics.
- Pilot will include five interactive virtual environments for children with autism to practice life skills.
- Sirica Therapeutics plans to establish approximately 100 autism treatment centers nationwide.
- Virtuix recently sold Omni One systems to the U.S. Department of Veterans Affairs for deployment at a VA medical center in Detroit.
- No financial terms, revenue projections, or clinical results were disclosed.
Financial Impact
No financial terms disclosed; pilot is non-revenue and speculative.
Risk Factors
- Pilot may fail to demonstrate clinical utility, limiting adoption.
- No disclosed financial commitment from partners; revenue timeline uncertain.
- Healthcare market entry is early-stage and unproven for Omni One.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3367553 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.13 | awaiting T+20 | — | $0.6500 (+42.48%) |
Sep 30, 2026 26d ago | 8-K | $1.21 | awaiting T+20 | — | $0.6500 (−46.28%) |
Sep 23, 2026 4w ago | Press Release | $1.13 $0.7791 | ▼ −31.05% | ▼ −31.74% | $0.6500 (−42.48%) |
Aug 12, 2026 10w ago | Press Release | $1.70 | awaiting T+20 | — | $0.6500 (−61.76%) |
Aug 6, 2026 11w ago | DEFA14A | $1.69 $1.31 | ▼ −22.49% | ▼ −23.09% | $0.6500 (−61.54%) |
Aug 6, 2026 11w ago | 8-K | $1.69 $1.31 | ▲ +22.49% | ▲ +23.09% | $0.6500 (+61.54%) |
Aug 5, 2026 11w ago | Insider Cluster | $1.69 $1.31 | ▼ −22.49% | ▼ −23.09% | $0.6500 (−61.54%) |
Jul 31, 2026 12w ago | Insider Cluster | $1.56 $1.33 | ▲ +14.74% | ▲ +15.98% | $0.6500 (+58.33%) |
Jul 29, 2026 12w ago | 10-K/A | $1.61 $1.38 | ▼ −14.29% | ▼ −18.25% | $0.6500 (−59.63%) |
Jul 21, 2026 13w ago | 8-K / 424B5 | $2.29 $1.59 | ▲ +30.57% | ▲ +33.13% | $0.6500 (+71.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers